Efficacy of trazodone for delirium in cancer patients: a systematic review
Not Applicable
Not yet recruiting
- Conditions
- Cancer
- Registration Number
- JPRN-UMIN000051799
- Lead Sponsor
- Mie University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
1.Duplicate publications 2.Conference proceedings
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of delirium
- Secondary Outcome Measures
Name Time Method Duration of delirium, somnolence, tumbling and falls.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie trazodone's efficacy in managing cancer-related delirium?
How does trazodone compare to haloperidol or quetiapine in treating delirium among oncology patients?
Are there specific biomarkers like inflammation markers or genetic profiles predicting trazodone response in delirious cancer patients?
What adverse events such as sedation or QT prolongation are associated with trazodone use in delirium treatment for malignancy patients?
What alternative serotonin antagonists or combination therapies show promise for delirium management in advanced cancer populations?